Beacon Investment Advisory Services Inc. Grows Stock Holdings in Amgen Inc. $AMGN

Beacon Investment Advisory Services Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,129 shares of the medical research company’s stock after acquiring an additional 2,540 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Amgen were worth $18,372,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Board of the Pension Protection Fund bought a new stake in shares of Amgen during the 4th quarter valued at $26,000. Howard Hughes Medical Institute bought a new position in Amgen in the 2nd quarter worth about $32,000. Olistico Wealth LLC bought a new position in Amgen in the 4th quarter worth about $33,000. Cloud Capital Management LLC purchased a new position in Amgen during the 3rd quarter valued at about $34,000. Finally, Saranac Partners Ltd purchased a new position in Amgen during the 3rd quarter valued at about $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $348.77 on Monday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company’s 50 day moving average is $362.59 and its 200 day moving average is $330.59. The stock has a market cap of $188.01 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period in the previous year, the business posted $5.31 earnings per share. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is currently 70.84%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on AMGN shares. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a report on Tuesday, January 20th. UBS Group boosted their price objective on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Daiwa Securities Group upped their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Cantor Fitzgerald increased their target price on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Finally, Piper Sandler boosted their price target on shares of Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has an average rating of “Hold” and an average target price of $354.60.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.